辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFE 辉瑞

未开盘 05-08 16:00:00 EDT

28.27

+0.50

+1.80%

盘后28.26

-0.01-0.04%

19:59 EDT

最高28.34	最低27.52	成交量3,909万
今开27.70	昨收27.77	日振幅2.95%
总市值1,601亿	流通市值1,598亿	总股本56.63亿
成交额10.99亿	换手率0.69%	流通股本56.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":28.27,"timestamp":1715198400000,"preClose":27.77,"halted":0,"volume":39087790,"hourTrading":{"tag":"盘后","latestPrice":28.26,"preClose":28.27,"latestTime":"19:59 EDT","volume":871647,"amount":24612440.0858,"timestamp":1715212798329},"delay":0,"floatShares":5653824941,"shares":5662541291,"eps":-0.05851,"marketStatus":"未开盘","marketStatusCode":0,"change":0.5,"latestTime":"05-08 16:00:00 EDT","open":27.7,"high":28.34,"low":27.52,"amount":1099399129.35832,"amplitude":0.029528,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.05851,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1715241600000},"adr":0,"listingDate":-819144000000,"adjPreClose":27.77,"adrRate":0,"dividendRate":0.058366,"preHourTrading":{"tag":"盘前","latestPrice":27.72,"preClose":27.77,"latestTime":"09:29 EDT","volume":161200,"amount":4466779.46,"timestamp":1715174999956},"postHourTrading":{"tag":"盘后","latestPrice":28.26,"preClose":28.27,"latestTime":"19:59 EDT","volume":871647,"amount":24612440.0858,"timestamp":1715212798329},"volumeRatio":0.553267,"optionData":{"bulkOrders":[{"symbol":"PFE","call":true,"expireDate":1715313600000,"strike":"27.5","timestamp":1715195884998,"price":0.7799999713897705,"volume":29210,"amount":2278380,"type":"+"},{"symbol":"PFE","call":true,"expireDate":1715918400000,"strike":"26.0","timestamp":1715195884998,"price":2.240000009536743,"volume":25720,"amount":5761280,"type":"-"}]}},"requestUrl":"/m/hq/s/PFE/tweets","defaultTab":"tweets","newsList":[{"id":"2433727643","title":"更新版 1-据彭博新闻社报道，辉瑞公司同意就超过 10,000 起 Zantac 诉讼达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2433727643","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2433727643?lang=zh_cn&edition=full","pubTime":"2024-05-08 22:43","pubTimestamp":1715179415,"startTime":"0","endTime":"0","summary":"     路透5月8日 - 彭博新闻社周三援引知情人士的话报道说，辉瑞  已同意就1万多起与现已停产的胃灼热药物Zantac有关的癌症风险诉讼 达成和解。报道称，这些协议涉及美国 州法院的案件，但并没有 完全解决该公司面临的Zantac索赔 问题，并补充说，交易的财务细节尚未立即公布。2020 年，美国食品和药物管理局要求制药商从市场上撤下 Zantac 及其仿制药，因为在该药样品中发现了一种名为 NDMA 的致癌物质。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433452722","title":"辉瑞同意解决 1 万多起善达（Zantac）癌症诉讼 - 彭博新闻社","url":"https://stock-news.laohu8.com/highlight/detail?id=2433452722","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2433452722?lang=zh_cn&edition=full","pubTime":"2024-05-08 22:26","pubTimestamp":1715178389,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透5月8日 - 彭博新闻社周三援引熟悉该交易的人士的话报道说，辉瑞公司  已同意就1万多起与现已停产的胃灼热药善达克（Zantac）有关的癌症风险案件达成和解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433252769","title":"“诺礼”垄断神话生变？药企频推新药，“减肥双雄”面临挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2433252769","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433252769?lang=zh_cn&edition=full","pubTime":"2024-05-08 10:19","pubTimestamp":1715134777,"startTime":"0","endTime":"0","summary":"其中包括诺和诺德每周为糖尿病和肥胖患者注射的一种名为CagriSema的药物。与此同时，礼来公司正在研究一种名为利特鲁肽的实验性药物，该药物已进入后期试验阶段。尽管MariTide会产生一些相同的副作用，但Phipps称，每月或每季度注射一次这种药物，与每周注射一次相比，会减少恶心的天数。一项中期试验发现，超重或肥胖","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1118577.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2433730457","title":"辉瑞公司报告杜兴氏症基因治疗研究中的患者死亡病例","url":"https://stock-news.laohu8.com/highlight/detail?id=2433730457","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2433730457?lang=zh_cn&edition=full","pubTime":"2024-05-08 04:57","pubTimestamp":1715115435,"startTime":"0","endTime":"0","summary":"    路透5月7日 - 辉瑞公司周二告诉路透，在一项测试辉瑞  基因疗法治疗杜氏肌营养不良症的中期试验中，一名小男孩因心脏骤停而死亡。\"该公司发言人在一份电子邮件回复中告诉路透：\"据报告，在第二阶段DAYLIGHT研究中，一名参与者发生了致命的严重不良事件，即心脏骤停。该试验测试了2岁至4岁以下患有DMD的男孩，DMD是一种遗传性肌肉萎缩症，大多数患者缺乏能保持肌肉完整的蛋白质dystrophin。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433316127","title":"辉瑞下跌1.21%，报27.82美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433316127","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2433316127?lang=zh_cn&edition=full","pubTime":"2024-05-08 03:23","pubTimestamp":1715109803,"startTime":"0","endTime":"0","summary":"5月8日，辉瑞(PFE)盘中下跌1.21%，截至03:23，报27.82美元/股，成交9.38亿美元。财务数据显示，截至2024年03月31日，辉瑞收入总额148.79亿美元，同比减少19.51%；归母净利润31.15亿美元，同比减少43.8%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/08032340555804.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433827403","title":"ROS1阳性肺癌“三国杀”！正大天晴就位，双寡头辉瑞、罗氏格局生变？","url":"https://stock-news.laohu8.com/highlight/detail?id=2433827403","media":"医药经济报","top":-1,"share":"https://www.laohu8.com/m/news/2433827403?lang=zh_cn&edition=full","pubTime":"2024-05-06 23:02","pubTimestamp":1715007721,"startTime":"0","endTime":"0","summary":"ROS1阳性非小细胞肺癌赛道迎来新的搅局者。但在这次正大天晴的安奈克替尼获批上市前，国内获批用于ROS1基因重排的治疗药物，仅有辉瑞的克唑替尼和罗氏的恩曲替尼。而此番正大天晴的安奈克替尼获批上市，将有望打破现有ROS1阳性晚期NSCLC的治疗瓶颈，助力患者实现长期生存。此次正大天晴申请上市的适应症则是基于一项评价安奈克替尼单药治疗ROS1阳性NSCLC受试者疗效和安全性的II期单臂、多中心临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405062303598ae1989f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405062303598ae1989f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433424309","title":"花旗前高管安德鲁·鲍姆将任辉瑞首席战略与创新官","url":"https://stock-news.laohu8.com/highlight/detail?id=2433424309","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2433424309?lang=zh_cn&edition=full","pubTime":"2024-05-06 19:46","pubTimestamp":1714995976,"startTime":"0","endTime":"0","summary":"辉瑞5月6日宣布，安德鲁·鲍姆（Andrew Baum）将出任公司首席战略与创新官兼执行副总裁，6月3日起生效。加入辉瑞前，鲍姆曾在花旗银行担任全球医疗保健部主管、股票研究董事总经理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061946167a584449&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405061946167a584449&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433445521","title":"辉瑞ADC药物TIVDAK获美国FDA完全批准，用于治疗复发性或转移性宫颈癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2433445521","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2433445521?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:46","pubTimestamp":1714985188,"startTime":"0","endTime":"0","summary":"5月6日，再鼎医药官微宣布，合作伙伴辉瑞公司和Genmab联合宣布美国食品药品监督管理局（FDA）已经批准了TIVDAK®（tisotumab vedotin-tftv）的补充生物制剂许可申请（sBLA），完全批准其用于治疗化疗期间或化疗后疾病发生进展的复发性或转移性宫颈癌患者。（界面新闻）\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-05-06/doc-inauhrwv3095368.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433427104","title":"再鼎医药合作伙伴：辉瑞和Genmab获批TIVDAK用于治疗宫颈癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2433427104","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2433427104?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:31","pubTimestamp":1714984305,"startTime":"0","endTime":"0","summary":"两项试验均显示，TIVDAK在治疗对象中显示出良好的疗效和可接受的安全性。再鼎医药表示，TIVDAK的获批将为宫颈癌患者提供一种新的治疗选择，有助于改善患者的预后。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050617544787d8100e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050617544787d8100e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433431294","title":"辉瑞(PFE)用于治疗复发性或转移性宫颈癌的ADC药物TIVDAK获美FDA完全批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2433431294","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2433431294?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:24","pubTimestamp":1714983859,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药(09688、ZLAB)宣布，合作伙伴辉瑞公司(PFE)和Genmab联合宣布美国食品药品监督管理局（FDA）已经批准了TIVDAK®（tisotumab vedotin-tftv）的补充生物制剂许可申请（sBLA），完全批准其用于治疗化疗期间或化疗后疾病发生进展的复发性或转移性宫颈癌患者。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NzhiZDQ4N2Q4MzQwNjg3YThiMjQyY2JmMzE4MDg0MDY1NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NzhiZDQ4N2Q4MzQwNjg3YThiMjQyY2JmMzE4MDg0MDY1NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"275553","is_publish_highlight":false,"gpt_icon":0},{"id":"2433460421","title":"大行评级｜大摩：上调辉瑞目标价至29美元 对今年前景持谨慎乐观态度","url":"https://stock-news.laohu8.com/highlight/detail?id=2433460421","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2433460421?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:41","pubTimestamp":1714963267,"startTime":"0","endTime":"0","summary":"摩根士丹利发表报告指出，辉瑞首季业绩超预期，并重申对今年收入指引介乎585亿至615亿美元，相对于该行最新预期及市场预期各为613亿与599亿美元。该行引述辉瑞管理层指出，对今年余下时间的前景持谨慎乐观态度，包括毛利率方面。该行将辉瑞今年每股盈利预测上调0.2美元，维持“与大市同步”评级，目标价由28美元上调至29美元，关注公司新产品周期/管线进展，以应对专利失效的影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050610411587d67bf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050610411587d67bf0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432994083","title":"《大行》大摩升辉瑞(PFE.US)目标价至29美元  对今年前景谨慎乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=2432994083","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432994083?lang=zh_cn&edition=full","pubTime":"2024-05-03 10:13","pubTimestamp":1714702380,"startTime":"0","endTime":"0","summary":"摩根士丹利发表报告指出，辉瑞首季业绩超预期，并重申对今年收入指引介乎585亿至615亿美元，相对于该行最新预期及市场预期各为613亿与599亿美元。该行引述辉瑞管理层指出，对今年余下时间的前景持谨慎乐观态度，包括毛利率方面。该行将辉瑞今年每股盈利预测上调0.2美元，维持“与大市同步”评级，目标价由28美元上调至29美元，关注公司新产品周期/管线进展，以应对专利失效的影响。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201022142503154_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201022142503154_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1347176/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2432766951","title":"健康巡诊：快速检测败血症的新测试","url":"https://stock-news.laohu8.com/highlight/detail?id=2432766951","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432766951?lang=zh_cn&edition=full","pubTime":"2024-05-03 04:58","pubTimestamp":1714683482,"startTime":"0","endTime":"0","summary":"今天，我们为您带来了一项新检测的数据，它可以在医院环境中快速检测出可能危及生命的败血症。新型测试可快速确认败血症一份新的报告显示，一种新的客观检验有助于加快对可能危及生命的败血症的诊断。据制造商Cytovale称，IntelliSep检测去年获得了美国批准，用于检测成人败血症，它能在10分钟内通过血液样本提供免疫激活和败血症风险分层的信息。该试验对 490 名吸烟者进行了跟踪调查，这些人被随机分配接受为期六周的伐尼克兰或 CNRT 治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432909607","title":"大行评级｜摩根大通：辉瑞首季核心产品销售符合预期 维持“中性”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2432909607","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2432909607?lang=zh_cn&edition=full","pubTime":"2024-05-02 22:17","pubTimestamp":1714659460,"startTime":"0","endTime":"0","summary":"摩根大通发表研报指，辉瑞首季核心产品Paxlovid销售表现符合预期，毛利率更超出预期达到近80%，对比该公司全年指引为约70%。考虑到辉瑞的股价在短期内或会波动，该行维持“中性”评级，认为要有更强劲的新药销售表现或管线的进一步进展，市场才会明显改变现有看法，目标价为30美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405022217448b6d4761&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405022217448b6d4761&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432785206","title":"莫德纳 季度销售额超出预期，但同比大幅下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2432785206","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432785206?lang=zh_cn&edition=full","pubTime":"2024-05-02 18:30","pubTimestamp":1714645806,"startTime":"0","endTime":"0","summary":"莫德纳公司唯一上市的COVID-19疫苗Spikevax的销售额比上年同期下降了91%，为1.67亿美元，但超过了分析师预期的9750万美元。莫德纳将进入辉瑞  和葛兰素史克  已经在争夺份额的RSV疫苗市场。莫德纳重申了2024年40亿美元的销售预期，这是自2020年底其COVID疫苗获得美国紧急授权以来最低的年收入数字。莫德纳 说，它打算今年向监管机构申请批准其流感疫苗。该公司称，本季度的销售成本共计 9,600 万美元，其中包括 2,700 万美元的生产缩减成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432621281","title":"BUZZ-券商观点：辉瑞公司的增长预测附带注意事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2432621281","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432621281?lang=zh_cn&edition=full","pubTime":"2024-05-02 17:29","pubTimestamp":1714642195,"startTime":"0","endTime":"0","summary":"** 然而，相信该公司有能力管理债务偿还和股息** 摩根大通 表示，未来有必要加强新产品的推出和/或在产品线上取得进一步进展。** 摩根大通预计全年毛利率和口服抗病毒药物 Paxlovid 的销售额将有所改善** Cantor Fitzgerald 称，降低成本将使该公司在扩大利润率和提高财务回报方面站稳脚跟** Truist Securities 认为近期 \"随着 PFE 的商业化运作，其业绩将实现增长\"，并认为包括 Litfulo、Velsipity 和大量肿瘤产品组合在内的主要产品的标签扩展将带来长期增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432184376","title":"《大行》摩通：辉瑞(PFE.US)首季核心产品符预期惟毛利超预期  全年指引或上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2432184376","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432184376?lang=zh_cn&edition=full","pubTime":"2024-05-02 11:11","pubTimestamp":1714619460,"startTime":"0","endTime":"0","summary":"摩根大通发表研报指，辉瑞公布首季业绩，核心产品Paxlovid销售表现符合预期，毛利率更超出预期达到近80%，对比该公司全年指引为约70%。虽然辉瑞管理层今次未有调整产品销售额及毛利率全年指引，但摩通相信投资者不会对辉瑞今年业绩表现持续增长或调整指引感到惊讶，将今明两年经调整每股盈利预测上调至2.45及2.57美元，对比今年度公司指引为介乎2.15至2.35美元。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201022142503154_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201022142503154_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346834/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2432276663","title":"隔夜美股全复盘(5.2)| 三大股指上演过山车行情，在美联储公布利率决议后先涨后跌，AMD跌近9%；高通盘后一度涨超5%，一季度业绩和二季度指引好于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2432276663","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2432276663?lang=zh_cn&edition=full","pubTime":"2024-05-02 07:18","pubTimestamp":1714605498,"startTime":"0","endTime":"0","summary":"三大股指上演过山车行情，在美联储公布利率决议后先涨后跌，AMD跌近9%；高通盘后一度涨超5%，一季度业绩和二季度指引好于预期","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/726034","is_publish_highlight":false,"gpt_icon":1},{"id":"2432501190","title":"BUZZ-COVID-19 疫苗第一季度销售额低于预期，BioNTech 下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2432501190","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432501190?lang=zh_cn&edition=full","pubTime":"2024-05-01 23:07","pubTimestamp":1714576047,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    5月1日 - ** 在美国上市的生物技术公司   股价下跌1.5%，至87.48美元 ** 辉瑞  是BNTX公司COVID-19疫苗的合作伙伴，该公司第一季度 (link)，销售额为3.54亿美元，低于预期的4.965亿美元 - LSEG ** 券商 TD Cowen 预计 \"该专营权的未来可能取决于流感/COVID-19 联合疫苗的成功\"，并补充说该疫苗目前正处于后期开发阶段。 ** 该券商还预计，BNTX 的重点将放在推进其中后期肿瘤管线上。** 年初至今，BNTX 的股价下跌了 16.9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432150849","title":"辉瑞盘中异动 快速上涨5.11%报26.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432150849","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432150849?lang=zh_cn&edition=full","pubTime":"2024-05-01 21:48","pubTimestamp":1714571310,"startTime":"0","endTime":"0","summary":"北京时间2024年05月01日21时48分，辉瑞股票出现波动，股价大幅上涨5.11%。截至发稿，该股报26.93美元/股，成交量1289.21万股，换手率0.23%，振幅3.33%。辉瑞股票所在的制药行业中，整体涨幅为0.02%。辉瑞在全球销售这些产品，国际销售额占其总销售额的近 50%。上一季度，辉瑞实现营收142亿美元，同比下降42%，主要是由于其新冠产品的销售额下降。辉瑞的调整后净利润率暴跌逾2200个基点，至4.2%，原因是26亿美元的重组成本，SG&A和研发费用占营收的百分比同比上升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012148327a57dc04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012148327a57dc04&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":0.0401},{"period":"1month","weight":0.0636},{"period":"3month","weight":0.0254},{"period":"6month","weight":-0.041},{"period":"1year","weight":-0.2653},{"period":"ytd","weight":-0.0181}],"compareEarnings":[{"period":"1week","weight":0.0337},{"period":"1month","weight":-0.0029},{"period":"3month","weight":0.0379},{"period":"6month","weight":0.1738},{"period":"1year","weight":0.2586},{"period":"ytd","weight":0.0881}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.00126},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.007167},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015985},{"month":4,"riseRate":0.6,"avgChangeRate":0.019475},{"month":5,"riseRate":0.511111,"avgChangeRate":0.008419},{"month":6,"riseRate":0.5,"avgChangeRate":0.002739},{"month":7,"riseRate":0.477273,"avgChangeRate":0.010684},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.000087},{"month":9,"riseRate":0.454545,"avgChangeRate":0.004027},{"month":10,"riseRate":0.659091,"avgChangeRate":0.014878},{"month":11,"riseRate":0.704545,"avgChangeRate":0.030213},{"month":12,"riseRate":0.5,"avgChangeRate":0.0093}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}